Huakang Biomedical Holdings Co Ltd
HKEX:8622
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (1.8), the stock would be worth HK$0.15 (53% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.8 | HK$0.33 |
0%
|
| 3-Year Average | 1.8 | HK$0.15 |
-53%
|
| 5-Year Average | 1.5 | HK$0.13 |
-61%
|
| Industry Average | 0.9 | HK$0.08 |
-75%
|
| Country Average | 1.4 | HK$0.12 |
-64%
|
Forward EV/S
Today’s price vs future revenue
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| HK |
H
|
Huakang Biomedical Holdings Co Ltd
HKEX:8622
|
167.5m HKD | 3.8 | -29.1 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.9T JPY | 10.2 | 39.6 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.1B USD | 0 | 0 | |
| CH |
|
Alcon AG
SIX:ALC
|
29B CHF | 3.7 | 36.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
92B DKK | 4 | 22.8 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
12.7B USD | 2.9 | 30.8 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.2B GBP | 2.9 | 31.8 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
39.1B CNY | 8.1 | 23.7 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
905.8B JPY | 6.6 | 51.2 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | 99.2 | -37.8 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 2 | -15.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.6 |
| Median | 1.4 |
| 70th Percentile | 3.5 |
| Max | 59 382.5 |
Other Multiples
Huakang Biomedical Holdings Co Ltd
Glance View
Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.
